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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe recent development of 3D-liver stem cell cultures (hepatic organoids) opens upnew avenues for gene and/or stem cell therapy to treat
liver disease. To test safety and efficacy, a relevant large animalmodel is essential but not yet established. Because of its shared pathologies
and disease pathways, the dog is considered the best model for human liver disease. Here we report the establishment of a long-term
canine hepatic organoid culture allowing undifferentiated expansion of progenitor cells that can be differentiated toward functional he-
patocytes.We show that cultures can be initiated from fresh and frozen liver tissues using Tru-Cut or fine-needle biopsies. The use ofWnt
agonists proved important for canine organoid proliferation and inhibition of differentiation. Finally, we demonstrate that successful
gene supplementation in hepatic organoids of COMMD1-deficient dogs restores function and can be an effective means to cure copper
storage disease.INTRODUCTION
The mammalian liver has a strong regenerative capacity
through cell division ofmature hepatocytes and cholangio-
cytes. This is best demonstrated by the response of the
liver to partial hepatectomy or acute injury. However,
during chronic and severe injury, proliferation of mature
cells is impaired. In this situation, hepatic progenitor
cells (HPCs) become activated and may contribute to
liver regeneration. Despite this remarkable regenerative
capacity, treatment for liver failure or genetic liver dis-
eases remains necessary, and the only effective therapeutic
approach is orthotopic liver transplantation (Boulter et al.,
2013; Duncan et al., 2009; Russo and Parola, 2012).
Although whole organ transplantation is often successful,
the procedure is highly invasive and faces the problem of
liver donor shortage and the risk of graft rejection (Dalgetty
et al., 2009). Transplantation of mature hepatocytes has
been reported to improve liver function in patients with
metabolic disorders and acute liver failure. One major
impediment to using adult hepatocytes is their limited
supply, because long-term hepatocyte culture withmainte-
nance of their viability and functions has remained diffi-Stem Cell Rcult (McCarty et al., 2014; Vanhaecke and Rogiers, 2006).
The use of cryopreserved hepatocytes showed some clinical
success, giving potential for cell banking (Dhawan et al.,
2010; Hughes et al., 2012). Bi-potential HPCs that can
differentiate into hepatocytes and cholangiocytes have
been suggested to be a good alternative source for cell ther-
apy (Dalgetty et al., 2009). The advantages of usingHPCs or
HPC-derived hepatocytes over mature hepatocytes are that
HPCs can be expanded ex vivo and can be cryopreserved,
thereby potentially ensuring unlimited cell sources for
clinical application. In addition, when using adult stem
cells, autologous transplantation may be possible and
may abolish the need for lifelong and expensive immuno-
suppressive drugs (Russo and Parola, 2012). This could be
combined with gene correction before autologous trans-
plantation into a patient for the treatment of a genetic
disorder. Many attempts have been made to isolate and
develop adult liver stem cell culture systems (Guo et al.,
2012; He and Feng, 2011; Ichinohe et al., 2013; Kamiya
and Inagaki, 2015). However, a two-dimensional culture
format does not accurately resemble the three-dimensional
(3D) in vivo morphology, and most cell systems are genet-
ically stable for a maximum of 3 months (Scheers et al.,eports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 The Authors 895
2012). Recently, Huch et al. (2013, 2015) have succeeded in
deriving long-term stable liver stem cell cultures in 3D,
called hepatic organoids from mouse and human liver tis-
sues. These cultures could be clonally expanded from dam-
age-induced Lgr5+ stem cells or progenitors of mice, which
generated de novo hepatocytes and ductal cells during
injury in vivo. Both mouse and human organoids differen-
tiated into hepatocytes upon engraftment in injured
mouse livers (Huch et al., 2013, 2015). Finally, the in-depth
proof of genetic stability of the human hepatic organoids
(Huch et al., 2015) lends further credence to this culture
system as a logical source of cells for therapeutic repopula-
tion strategies.
To take the development and evaluation of new stem
cell-based treatment strategies forward, it is important to
use a relevant animal model to provide information on
safety and efficacy of treatments. The treatment of pet
dogs was reported to be informative in this perspective.
Several successful preclinical experiments in rodents have
been recapitulated in dogs to better mimic and bridge to
human trials (Kamimura et al., 2014;Mata et al., 2014; Rob-
erts et al., 2014). Furthermore, pathologies and their under-
lying pathways of disease, including the stem cell response,
are similar in the liver of men and dogs (Kruitwagen et al.,
2014; Schotanus et al., 2009; Spee et al., 2010). The devel-
opment of a canine hepatic organoid culture system is an
essential step to use dogs with liver diseases for the valida-
tion of stem cell therapies. Here we describe the establish-
ment of long-term canine hepatic organoids, provide
methods of isolation and cryopreservation that ensure suc-
cessful use of valuable patientmaterial, and show the use of
this cell system for in vitro disease modeling and gene sup-
plementation for gene therapy.RESULTS
Generation of Canine Hepatic Organoids
HPCs have been reported to reside in the biliary tree
(Boulter et al., 2013; Cardinale et al., 2011; Duncan et al.,
2009). Previously, adult murine and human HPCs were
expanded from the ductal compartment under organoid
culture conditions (Huch et al., 2013, 2015). To establish
canine HPCs cultures, we maintained biliary duct frag-
ments isolated from adult normal dog livers in 3D culture
by suspension in Matrigel droplets and R-spondin-1-based
culture medium (Figures 1A and 1C). Immunocytochem-
ical characterization of the fraction derived from isolation
showed that the cell suspension consisted of hepatocytes
(HepPar1), stellate cells or smooth muscle cells (a-smooth
muscle actin [a-SMA]), macrophages (MAC384), and endo-
thelial cells (Factor VIII) together with biliary duct frag-
ments (K19). Antibody details are given in Table S1. After896 Stem Cell Reports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 The1 week of culture, only K19+ cells remained (Figure 1B),
indicating the selection capacity of the expansionmedium
(EM). The EM for canine hepatic organoids contained
generic organoid factors Wnt3A, epidermal growth factor
(EGF), Noggin, and R-spondin-1, a potent Wnt agonist.
Similar to mouse hepatic organoid cultures, the addition
of fibroblast growth factor 10 (FGF10), hepatocyte growth
factor (HGF), nicotinamide, and gastrin was required
(Huch et al., 2013). Furthermore, culture of canine organo-
ids needed supplementation with a Wnt3A-conditioned
medium, Noggin, and a transforming growth factor b
(TGF-b) inhibitor throughout culture, and a Rho-kinase in-
hibitor was provided long term (Figure S1). Under these
conditions, canine duct fragments formed cysts within
24–48 hr and later grew out to larger organoids. Rho-kinase
inhibitor and TGF-b inhibitor were essential to retain the
culture for more than 3 months (Figure S1). The cultures
have been maintained for more than 8 months by weekly
passaging at a 1:4–1:8 split ratio and retained their char-
acteristics as described later. Ki67 staining showed the
strong proliferative activity of organoids (Figure 1C). Kar-
yotype analysis of organoids showed that most cells
(>85%) harbored normal chromosome numbers even after
8months in culture (n = 3 organoid cultures per time point,
100 cells counted per culture) (Figure 1D).
We investigated whether the presence of cells from
the in vivo HPC niche (hepatocytes, hepatic stellate cells,
macrophages, and endothelial cells) or the size of the
ducts, potentially reflecting the anatomical location of
the duct in the liver, affected the isolation and growth
of canine hepatic organoids. Organoids were cultured
from cell fractions immediately obtained after liver diges-
tion-containing ducts and other cell types, as well as cell
fractions highly enriched for biliary duct fragments, by
manual picking to minimize the presence of other cell
types. In addition, smaller or larger duct fragments ob-
tained using a 40 mm cell strainer were separately cultured.
None of the different cell compositions showed differ-
ences in culture potential, morphology, and gene expres-
sion profiles (Figures S2A and S2B). This implied that
the growth of organoids is independent from the extent
of signaling derived from the non-epithelial cellular
niche. For reasons of clinical application, organoids were
also derived from Tru-Cut biopsies, fine-needle aspirated
livers, and livers frozen up to 5 years in DMSO-based
freezing medium. All these methods resulted in the cul-
ture of canine hepatic organoids with the same morpho-
logical and gene expression characteristics as organoids
obtained from freshly explanted livers (Figures S2A and
S2B). Established canine hepatic organoids recovered
well after cryopreservation and maintained the potential
for long-term proliferation under the same culture condi-
tions (data not shown).Authors
Figure 1. Generation of Long-Term
Canine Hepatic Organoid Cultures Derived
from Adult Liver Tissue by Duct Isolation
(A) Scheme of organoid culture. Canine liver
tissue obtained from Tru-Cut biopsies, fine-
needle aspiration biopsies, or wedge biopsy
was enzymatically digested to achieve
biliary duct fragments. Isolated ducts were
cultured as described. See also Figures S1
and S2.
(B) Representative images of K19, HepPar1,
a-SMA, MAC384, and Factor VIII immuno-
staining in isolated fraction at day (d) 0,
showing the presence of biliary duct frag-
ments, hepatocytes, stellate cells, macro-
phages, and endothelial cells, respectively,
in the initial culture fraction, and K19
staining of organoids after 1 week in cul-
ture. HepPar1, a-SMA, MAC384, and Factor
VIII stainings were negative in organoids
1 week after isolation.
(C) Representative phase contrast images
of biliary ducts fragments and growing he-
patic organoids in culture at indicated time
points and passage numbers. The lower right
image is the 3D overlay of Ki67 and DAPI
immunofluorescence staining, indicating
strong proliferation in organoids.
(D) Representative karyotype of a cell with
normal chromosome number n = 78. The
graph shows the percentage of cells with
chromosome counts in organoids after 1, 3,
and 5–8 months in culture (n = 3 indepen-
dent organoid isolations per time point, 100
cells counted per culture); 1–3 loss (n = 75,
76, and 77); and 1 gain (n = 79).
See also Table S1.Gene expression analysis of long-term organoid cultures
derived from a single dog up to passage P28 (approximately
8 months) showed stable expression of stem cell (CD133
and LGR5), cholangiocyte (KRT19 and SOX9), and early he-
patocyte (FOXA1 andHNF4a) markers and very low expres-
sion of the mature hepatocyte (CYP3A12) marker overStem Cell Rtime (Figure 2A). Heat-map (Figure 2B) comparison of the
average gene expression from all stages (P2– P26) of the or-
ganoid cultures from three dogs and adult normal livers re-
vealed that cells in canine hepatic organoids have a higher
expression of the Wnt target gene and stem cell marker
Lgr5, the pluripotent stem cell markers CD133 and OCT4,eports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 The Authors 897
(legend on next page)
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and the bile duct or progenitor cell markers KRT19, SPP1,
SOX9, and HNF1b compared to normal liver. Early hepatic
marker genes such as alpha-fetoprotein (AFP), FOXA1,
FOXA2, and HNF4amostly had higher expression in orga-
noids compared to normal liver, whereas mature hepato-
cyte markers such as albumin, CYP3A12, and G6PC had
very low expression in organoids. The typical epithelial
marker E-cadherin had lower expression in organoids
when compared to normal liver, and hematopoietic and
mesenchymal cell markers were weakly detected or absent
in organoids (Figure 2B and a more detailed depiction in
Figure S3). Primer details are shown in Table S2. Overall,
these results confirmed the progenitor cell characteristics
of the hepatic organoid cultures.
Microscopic morphological examination of H&E-stained
organoids revealed that hepatic organoids generally con-
sisted of a single layer of cylindrical or low cuboidal epithe-
lial cells and sometimes a pseudostratified arrangement of
the cells. The size of the organoids varied between 50 and
500 mm approximately and sometimes reached a 1 mm
diameter. The individual cells measured 10–12 mm (data
not shown).
Immunohistochemistry confirmed that cells of the orga-
noids were strongly immunopositive for known liver stem
cell or cholangiocyte markers SOX9, HNF1b, K19, and K7.
Organoids also expressed the immature hepatocyte marker
HNF4A and showed patchy staining for albumin, which is
reported to be expressed not only by mature hepatocytes
but also by liver stem cells (Koike and Taniguchi, 2012; San-
cho-Bru et al., 2009) (Figure 2C). Mature hepatocyte
markers ZO1 and MRP2 were negative in organoids grown
in EM (Figure 3D). E-cadherin positivity proved the epithe-
lial nature of the organoids (Figure 2C). Antibody details
are given in Table S1.
Differentiation Potential of Canine Organoids
For induction of hepatocyte maturation of canine he-
patic organoids, Wnt agonists were withdrawn and Notch
signaling was inhibited. After 14 days of differentiation,
gene expression analysis revealed that canine hepatic
organoids showed a marked reduction in expression levels
of stem cell and cholangiocyte markers (CD133, TERT,Figure 2. Characterization of Canine Hepatic Organoids
(A) Gene expression analysis by qRT-PCR of different passage numbers o
dot plots (n = 2–3 biological replicates). See also Figure S3, which show
(B) Heatmap showing the comparative gene expression of stem cell, c
organoid isolations (mean of P2–P26 for each isolation, n = 4–6 passa
two adult liver tissues. Red, upregulated; green, downregulated.
(C) Representative images of immunohistochemical or cytochemical st
Organoids express cholangiocyte markers SOX9, HNF1b, K19, and K
E-cadherin.
See also Table S1.
Stem Cell RLGR5, SPP1, and SOX9) and acquired more characteristics
of hepatocytes, illustrated by an induction of hepatocyte
markers (AFP, HNF4A, and G6PC). Expression of HNF1b
was not changed in differentiated organoids (Figure 3A).
Hepatic enzymes alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) were induced upon differ-
entiation, and differentiated organoids secreted at least
4 times up to 50 times more albumin into the medium
compared to organoids cultured in EM and human hepa-
tocellular carcinoma cell lines HepG2 and Huh7. Fresh
primary hepatocytes produced 9 times more albumin
compared to differentiated organoids (Figure 3B). Hepato-
cyte cytochrome P450 function (Cyp3a activity) was also
induced in differentiated organoids toward the activity of
fresh primary hepatocytes (about 6.5 times higher) and
was slightly higher than HepG2 and Huh7 (Figure 3C).
Immunocytochemical staining of differentiated organoids
revealed a clear expression of mature hepatocyte character-
istics. Tight junction protein ZO1 was detectable in most
organoids after differentiation, and membrane protein
MRP2 was detected in some organoids. SOX9, a marker of
bile duct and stem cells, was clearly lost upon differentia-
tion (Figure 3D). The gene expression and functional
studies indicated no difference in differentiation potential
between organoids from lower (P3), middle (P12), and
higher (P22) passage numbers (Figures 3A–3C). Overall,
the results showed that canine hepatic organoids can be
differentiated towardmature hepatocytes with comparable
potential as mouse and human organoids and retain their
differentiation potential over time in culture (Huch et al.,
2013, 2015).
The Role of Wnt on HPC Biology
As opposed to mouse and human organoid cultures, the
culture of canine hepatic organoids partly relied on the
addition of Wnt3a. Wnt is a known regulator of stem cell
proliferation and differentiation during embryogenesis
(Nusse et al., 2008; Thompson and Monga, 2007), and it
provides maintenance of stem cell characteristics (Clevers
et al., 2014), which is essential for long-term stable cell cul-
tures. To investigate the role of Wnt in promoting long-
term canine organoid cultures, we investigated its effectf hepatic organoids derived from a single dog. Data are presented as
s the analysis of three additional independent organoid isolations.
holangiocyte (duct), and hepatocyte markers of three independent
ges per isolation, n = 2–3 biological replicates per passage) against
ainings of hepatic organoids compared to adult normal liver tissue.
7; hepatocyte markers HNF4a and albumin; and epithelial marker
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Figure 3. Hepatocellular Differentiation
of Canine Hepatic Organoids
(A) Dot plots show fold change of gene
expression of organoids cultured in DM from
different passage numbers (P3, P12, and
P22) toward organoids cultured in EM in the
same passage (n = 3 biological replicates).
Expression levels in primary hepatocytes are
shown in Figure S3.
(B) Hepatic enzymes and albumin secretion
of organoids in DM were measured and pre-
sented as fold change toward organoids in
EM (n = 3 biological replicates). Albumin
secretion in organoids was also compared to
HepG2, Huh7, and primary hepatocytes
(Hep.). Data presented as average ± SD.
(C) Cyp3a activity was measured in orga-
noids cultured in DM and presented as
fold change toward organoids in EM (n = 3
biological replicates). The graph compared
Cyp3a activity of organoids in DM to
HepG2, Huh7, and Hep. Data presented as
average ± SD.
(D) Representative images of immunohis-
tochemical stainings of organoids cultured
in EM and DM. Organoids in DM lose chol-
angiocyte markers such as SOX9 and gain
mature hepatocyte markers such as ZO1
and MRP2.
(A)–(D) show the results from one orga-
noid isolation. The experiment has been
performed on organoids derived from at
least three more different isolations and in
different passages, which all show similar
results.
See also Tables S1 and S2.on proliferation and differentiation. Organoidswere grown
in neutral EM (without Wnt agonists), medium supple-
mented with Wnt agonists (Wnt3a-conditioned medium
and R-spondin-1-conditioned medium), or medium sup-
plemented with the Wnt inhibitor IWP-2 for 24 hr. Using
a 5-ethynyl-20-deoxyuridine (EdU) incorporation assay to
measure DNA replication, we showed that activation of
Wnt signaling strongly enhances proliferation, whereas in-900 Stem Cell Reports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 Thehibition of Wnt suppressed proliferation of canine hepatic
organoids (Figure 4A). To address the role of Wnt in differ-
entiation status of the organoids, we treated cultures with
Notch inhibitor N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-
phenylglycine-1,1-dimethylethyl ester (DAPT, a standard
differentiation medium [DM]) or with Wnt inhibitor
IWP-2 in neutral DM (DM without DAPT). This showed
that Wnt inhibition-induced hepatocytic differentiationAuthors
Figure 4. Role of Wnt in Proliferation and Differentiation of Canine Hepatic Organoids
(A) Representative images of EdU and DAPI immunofluorescent whole-mount staining of organoids (3D overlay) cultured in neutral EM or
with Wnt inhibitor (IWP) or Wnt3a-conditioned medium with R-spondin (Wnt+R) added. The graph shows the percentage of EdU-positive
cells within an organoid (n = 3 biological replicates of at least 20 organoids).
(B) Gene expression analysis by qRT-PCR of organoids cultured in neutral DM with and without Wnt inhibitor (IWP), Notch inhibitor
(DAPT), or both (n = 4 biological replicates). Results are presented as fold change toward neutral DM.
(C) ALT, albumin secretion, and Cyp3a activity of organoids cultured in neutral DM with or without Wnt inhibitor (IWP), Notch inhibitor
(DAPT), or both (n = 3 biological replicates). Results are presented as fold change toward neutral DM.
The figure shows the results from one organoid isolation representative for a total of three independent organoid isolations with com-
parable experimental outcomes.
See also Table S2.to the same degree as Notch inhibition, as shown by down-
regulation of gene expression levels of SPP1 and upregu-
lation of HNF4A and Albumin gene expression, as well as
upregulation of the hepatocytic enzyme ALT, albumin
production, and cytochrome P450 activity compared to
neutral DM. Next, we assessed whether the combined inhi-
bition of Wnt and Notch signaling further increased the
degree of differentiation of the cells (IWP-2 and DAPT in
neutral DM). This co-inhibition did not result in an addi-
tive differentiation effect (Figures 4B and 4C). However,Stem Cell Rgene expression level of SPP1 in one of the three experi-
ments showed synergistic downregulation under DAPT
and IWP-2 treatment (data not shown). Taken together,
the results corroborate the importance of Wnt signaling
in the proliferation and maintenance of the stemness of
canine hepatic organoids.
Organoid Disease Modeling
To evaluate the use of canine hepatic organoids for disease
modeling, we isolated hepatic organoids from dogs with aneports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 The Authors 901
Figure 5. Restoration of Cellular Copper
Excretion by COMMD1 Gene Supplementa-
tion
(A) Representative phase contrast and fluo-
rescence images of wild-type, COMMD1/,
and LV-COMMD1-DsRed organoids, showing
successful transduction in LV-COMMD1-
DsRed organoids
(B) COMMD1 immunoblot of protein ex-
tracts from wild-type, COMMD1/, and
LV-COMMD1-DsRed organoids, showing
successful protein expression (n = 3 bio-
logical replicates). Beta-actin was used as
the loading control. The COMMD1 protein
in LV-COMMD1-DsRed organoids is larger
due to the remaining amino acids of
the cleavage site P2A added to the vector.
Quantification of protein presented as
average ± SD.
(C) Copper sensor measurement before and
after CuCl2 treatment of wild-type,
COMMD1/, and LV-COMMD1-DsRed orga-
noids (n = 3 biological replicates), showing
that LV-COMMD1-DsRed organoids success-
fully restored copper excretion.
(D) Representative phase contrast images
of wild-type, COMMD1/, and LV-COMMD1-
DsRed organoids after CuCl2 treatment. Deterioration of the culture and cell death (arrows) are presented in COMMD1
/ organoids.
This figure represents results of three repeated experiments with independent COMMD1/ organoids.autosomal recessive COMMD1 deficiency (Figure 5A). Our
previous longitudinal studies demonstrated that these
dogs develop copper-induced hepatitis highly similar to
Wilson’s disease in humans (Favier et al., 2012, 2015).
Intracellular copper levels of 14-day-differentiated organo-
ids subjected to high copper levels (500 mMCuCl2) for 3 hr
in the media were measured using a fluorescence-based
copper sensor (Cotruvo et al., 2015; Miller et al., 2006;
Zeng et al., 2006). This demonstrated that COMMD1/ or-
ganoids had a higher intracellular accumulation of copper
compared to normal organoids, similar to the copper excre-
tion defect in the in vivo situation (Figure 5C). This finding
clearly demonstrates the potential to use the canine hepat-
ic organoid technology for (translational) diseasemodeling
purposes, such as the COMMD1-deficient copper storage
disease as an important model for humanWilson’s disease.
We next assessed the potential for gene correction as a basis
for autologous gene therapy. By using DsRed-expressing
puromycin-selectable lentiviral vectors, the COMMD1
gene was transferred to COMMD1-deficient organoids.
Five passages after transduction, all cells in organoids
showedDsRed positivity, reflectingCOMMD1 gene transfer
(Figure 5A). Western blot analysis confirmed the accom-
plishment of COMMD1 gene insertion and protein expres-
sion in COMMD1/ organoids (Figure 5B). To determine a902 Stem Cell Reports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 Thefunctional effect of COMMD1 gene supplementation, we
again measured intracellular copper levels in differentiated
COMMD1/, LV-COMMD1-DsRed, and wild-type organo-
ids after 3 or 24 hr of CuCl2 treatment. The results revealed
that COMMD1 gene supplementation normalized cellular
copper content in LV-COMMD1-DsRed organoids to wild-
type levels. Twenty-four hours after exposure to high
copper levels, the COMMD1-deficient organoids showed
reduced viability due to copper accumulation, whereas
wild-type organoids and LV-COMMD1-DsRed organoids
remained normal (Figure 5D). These data suggest that LV-
COMMD1-DsRed and wild-type organoids were superior
in copper excretion compared to COMMD1-deficient orga-
noids and that gene transfer can successfully rescue the
phenotype in vitro.DISCUSSION
Three-dimensionally grown liver stem cells, so-called
hepatic organoids, have value in the field of regenerative
medicine, both for knowledge development and for thera-
peutic strategies such as (autologous) cell transplantation.
Findingmethods togenerate organoids fromtissues derived
by minimally invasive techniques is therefore critical. InAuthors
the current study,wedescribe the successful growthof orga-
noidsderived froma largepieceof fresh explanted liver, Tru-
Cut liver biopsy (14Gneedle), fine-needle aspiration biopsy
(22G needle), DMSO-based frozen livers, and even tissues
that were kept in cold DMEM with 1% fetal bovine serum
(FBS) for up to 2 days (data not shown). In all situations,
organoids formed within 1 week after isolation, could be
split at a ratio of 1:4–1:8 from the start, and remained
normal in chromosome number for more than 8 months,
in line with mouse and human hepatic organoids (Huch
et al., 2013, 2015). This flexibility of the tissue sampling
method, combined with the quick formation of organoids
in culture, proves their usefulness for the clinic and the po-
tential to use patient-derived tissues to circumvent theneed
for donor livers.
The organoids in this study were derived from dog
livers. The establishment of canine organoids is important
because dogs can fulfill a critical role as a clinically relevant
animal model in the translation from mouse to man. A
recent study elegantly showed that the treatment of
dogs with a new therapy can facilitate and improve the
translation to human practice. The promising anticancer
outcomes and risk-benefit profile obtained from a compar-
ative canine trial, in conjunction with the results observed
in rats, have encouraged Roberts et al. (2014) to move for-
ward to successful phase 1 studies in human patients.
Genetic studies have shown that many canine diseases
are similar to human diseases in terms of causative gene
mutation and phenotypic presentation. In particular,
the pathologies of spontaneous liver diseases are largely
shared by humans and dogs with respect to the histo-
logical and molecular characteristics of the underlying
pathways (Arends et al., 2009; Kruitwagen et al., 2014;
Schotanus et al., 2009; Spee et al., 2010). In addition, the
size of dogs is similar to that of human pediatric metabolic
liver patients, allowing the optimization of technical as-
pects such as route of injection or benefit of repetitive in-
jection of cells for transplantation or novel therapeutic
approaches.
Canine hepatic organoids show characteristics of the
putative liver stem or progenitor cells in the liver based
on their expression of biliary and hepatocellular markers
and their potential to differentiate toward hepatocytes.
The differentiated organoids obtained hepatocyte-specific
functions higher than those of human liver cell lines,
HepG2 and Huh7, although primary isolated hepato-
cytes still showed higher expression of albumin, compara-
ble to previous studies (Banas et al., 2007; Huch et al.,
2013). The inability to induce full hepatocyte maturation
in vitro is well known in the field, and perhaps this only
occurs after transplantation into a liver, as was shown for
mouse- and human-derived hepatic organoids or stem cells
that differentiated into mature hepatocytes upon engraft-Stem Cell Rment in the liver (Huch et al., 2013, 2015; Lu et al.,
2015). The HPC niche plays an important role in the deter-
mination of fate decision and probably supports in vivo
differentiation of transplanted HPCs (Boulter et al., 2012;
Espan˜ol-Sun˜er et al., 2012; Van Hul et al., 2011). Hepato-
cyte transplantation is currently more efficient than stem
cell transplantation (Azuma et al., 2007; Huch et al.,
2013; Yovchev et al., 2008). Therefore, further improve-
ment of hepatocyte differentiation in vitro, for example,
by altering the composition of the culture matrix, may
improve stem cell transplantation strategies. Moreover, it
will assist the use of patient-derived cells to model liver
diseases that require full hepatocyte differentiation for dis-
ease manifestation, toxicology studies, or personalized
treatment strategies.
To culture genetically stable canine organoids for more
than 8 months, we modified murine hepatic organoid
EM (Huch et al., 2013). Continuous supply of Wnt ago-
nists, inhibitors of TGF-b, and Rho-associated protein ki-
nase (ROCK) inhibitors was necessary for long-term viable
canine cultures. Different species require specific and
slightly different intervention with pathways involved
in hepatic cell fate control and differentiation (Lemaigre,
2009; Si-Tayeb et al., 2010) to obtain long-term stable
cultures. Neither mouse nor human hepatic organoids
need the addition of Wnt3a for long-term culture (Huch
et al., 2013, 2015). Recent work reported on a pericentral
hepatocyte population in mice that contributes to main-
tenance of hepatocytes in a Wnt-dependent fashion
(Wang et al., 2015). Our data demonstrate that for canine
hepatic organoids, Wnt is important for proliferation and
for maintenance of long-term stability, while the inhibi-
tion of Wnt enhanced differentiation. This information
is interesting in view of the role of Wnt in canine HPCs
during liver disease and may partly explain the lack of dif-
ferentiation during chronic hepatitis or lobular dissecting
hepatitis in dogs (Schotanus et al., 2014). It shows that or-
ganoid cultures are a useful tool to study stem cell biology
and may serve to find potential therapeutic targets to
stimulate endogenous adult HPCs to repopulate the liver
during diseases.
Transplantation of wild-type differentiatedmouse hepat-
ic organoids into Fah/ mice resulted in full maturation
into hepatocytes and the extended lifetime of the mice
(Huch et al., 2013). This study demonstrated the potential
of organoids for transplantation goals, although engraft-
ment efficiency needs to be enhanced to obtain a complete
liver function rescue (Grompe, 2014). An important thera-
peutic approach could be the autologous transplantation
of genetically corrected organoids, derived from metaboli-
cally diseased liver patients. For that purpose, successful
gene correction must be performed in vitro. In this study
we used our dog model of COMMD1-deficiency-inducedeports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 The Authors 903
copper storage disease. This gene mutation causes copper
toxicosis with a phenotype similar to Wilson’s disease in
humans (Favier et al., 2012, 2015; Fieten et al., 2014).
COMMD1-deficient organoids showed enhanced copper
storage in culture. Upon transduction with a COMMD1
construct, successful restoration of copper excretion and
enhanced viability upon copper exposure was achieved.
These experiments demonstrated the feasibility to perform
successful gene correction in hepatic organoids, a key pre-
requisite for autologous transplantation therapy. More-
over, they confirm that organoids represent a powerful
tool for disease modeling of canine liver diseases that serve
as a robust translational model for human liver diseases
such as Wilson’s disease (Favier et al., 2012). The first
functional restoration experiments have been performed
in human cystic fibrosis patient-derived intestinal organo-
ids using CRISPR (clustered regularly interspaced short
palindromic repeats)/Cas9 genome editing. This corrected
disease-causing mutations (Schwank et al., 2013) and illus-
trated the amazing therapeutic potential of combining
organoids and genome editing technology. Twomain chal-
lenges that remain for the use of genetically corrected orga-
noids in clinical application are graft rejection and tumor-
igenicity. First, immune reaction due to non-self protein in
transduced organoids may occur despite autologous trans-
plantation; therefore, (short term) immunosuppressive
therapy will be necessary. Second, genetic instability may
be introduced during culture upon transduction and in-
crease the risk of tumor formation. This could be assessed
in long-term experiments using large translational models
such as the COMMD1/ dog.
Taken together, the ability to culture hepatic organoids
obtained directly from patients opens several new research
and therapeutic avenues. First, they can be used as a system
to investigate fundamental research questions in relevant
patient material of different species. Second, it provides
a platform for pre-clinical modeling of liver diseases. Third,
these cells have great potential as an alternative source
for autologous stem cell therapies. Methods described
in this paper pave the way to culture organoids from
fresh and frozen patient samples derived with low-invasive
techniques. The prospect of using hepatic organoids in cell
therapy is encouraging but does require strong validation
in the clinical setting. The development of liver stem cell
cultures from the dog as a large animal model is an impor-
tant step to overcome the challenges of moving from basic
translational research toward application in human pa-
tients. Treatment of pet dogs in an academic clinical envi-
ronment has the benefit to serve both veterinary and hu-
man medicine. The next step is therefore to perform
transplantation studies in dogs to assess long-term safety,
efficacy, and tumorigenicity of organoids for treatment of
liver diseases.904 Stem Cell Reports j Vol. 5 j 895–907 j November 10, 2015 j ª2015 TheEXPERIMENTAL PROCEDURES
Isolation of Canine Biliary Duct Fragments and
Culture of Hepatic Organoids
The use of liver tissues from dogs was approved by Utrecht Uni-
versity’s ethical committee. Fresh canine adult normal liver tissues
were taken from liver explants (unless otherwise noted), 14G Tru-
Cut needle biopsies, or fine-needle aspiration (22G) fromdogs used
in non-liver-related research (the reduce, reuse, recycle policy of
Utrecht University). Liver tissues from COMMD1-deficient dogs
were collected and frozen in a previous experiment approved by
Utrecht University’s ethical committee, as required under Dutch
legislation (ID2007.III.06.080). No animals were harmed or killed
for the purpose of this study. Liver tissues were used for isolation
immediately or frozen in DMSO-based freezing medium (Gibco)
under a slow-freezing method and thawed rapidly in a 37C water
bath before isolation. Visible bile ducts were removed before isola-
tion. After mechanical dissection, liver tissues were enzymatically
digested in DMEM (Gibco) with 1% FBS (Gibco) containing
0.3 mg/ml of type II collagenase (Gibco) and 0.3 mg/ml of dispase
(Gibco) at 37C for a total of 3–5 hr until biliary duct fragments
appeared. The isolated ducts were then mixed with Matrigel
(BD Biosciences) and seeded. Culture medium was added after
gelation of theMatrigel. EMwas based onAdvDMEM/F12 (Invitro-
gen) supplemented with 1% B27 (Invitrogen), 1%N2 (Invitrogen),
1.25 mM N-acetylcysteine (Sigma-Aldrich), 10 nM gastrin (Sigma-
Aldrich), 200 ng/ml of EGF (Invitrogen), 5% R-spondin-1-condi-
tioned medium (provided by Calvin J. Kuo), 100 ng/ml of FGF10
(PeproTech), 10 mM nicotinamide (Sigma-Aldrich), 25 ng/ml
of HGF (PeproTech), 100 ng/ml of Noggin (PeproTech), 30%
Wnt3a-conditioned medium (prepared as in Willert et al., 2003),
10 mM Y-27632 2HCl (ROCK inhibitor, Selleckchem), and 0.5 mM
A83-01 (TGFb inhibitor, Tocris Bioscience). Organoids were split
by removal from Matrigel using cold AdvDMEM/F12, mechan-
ical dissociation into smaller fragments, and transfer into fresh
Matrigel. Passage was performed weekly at a 1:4–1:8 split ratio.
The medium was changed every second day.
Karyotyping of Hepatic Organoids
Organoids (after 1, 3, and 5–8 months in culture) in the exponen-
tial growth phase were arrested in metaphase with 0.05 mg/ml
of colcemid (Gibco) for 6 hr at 37C. Next, organoids were washed
and dissociated into single cells using TrypLE select enzyme
(Gibco). Cell pellets were then incubated for 10 min in 56 mM
KCl and fixed with methanol:acetic acid (3:1) after KCl was dis-
carded. Finally, cells were dropped on slides and chromosomes
from at least 100 metaphase arrested cells per organoid culture
(three organoid cultures per time point) were stained with 40,6-di-
amidino-2-phenylindole (DAPI, Sigma-Aldrich) and counted.
Three independent organoid cultures derived from different dogs
were used at each time point. Photographs were taken using a
confocal microscope (Leica).
Hepatocyte Differentiation
For induction of hepatocyte maturation, hepatic organoids were
seeded in Matrigel and kept 2 days under EM, as described previ-
ously. Then Wnt3a-conditioned medium, R-spondin-1, HGF,Authors
FGF10, gastrin, nicotinamide, and ROCK inhibitor were with-
drawn from the medium and 10 nMDAPT (Selleckchem), a Notch
inhibitor, was added (day 0). From day 6, 30 mM dexamethasone
(Sigma-Aldrich) was supplemented in the medium. The medium
was changed every other day for a period of 14 days.
Hepatocyte Functional Studies
For determination of albumin secretion, a culture medium from
differentiated organoids was collected at day 14 of differentiation.
Protein in the medium was concentrated using Amicon Ultra
centrifugal filters (Millipore), and the amount of albumin was
measured using a DxC-600 Beckman (Beckman Coulter). The
values were normalized for total cell number. For measurement
of cytochrome P450 activity, 14-day-differentiated organoids
were removed from Matrigel and incubated in 50 mM luciferin-
PFBE substrate (Promega) in hepatozymemedium (Gibco) contain-
ing 10% FBS for 8 hr at 37C. Cyp3a activity was then measured
with a luminometer using the P450-Glo cytochrome P450 assay
kit according to the manufacturer’s instructions (Promega). For
comparative analysis, freshly isolated canine hepatocytes were
used (Arends et al., 2009). Furthermore, human cell lines HepG2
(cultured in DMEM with 10% FBS) and Huh 7 (cultured in
DMEM with 10% FBS) were included for comparative functional
analysis.
For measurement of the expression of hepatic enzymes in differ-
entiated organoids, cells were lysed in milliQ at day 14 and stored
at 20C. ALT and AST were measured using the DxC-600 Beck-
man (Beckman Coulter) standard protocols, and values were cor-
rected for total cell counts.
Wnt Interference Experiments
For assessment of the role of Wnt signaling pathway in organoid
proliferation, neutral EM consisting of standard EM without
Wnt3a-conditioned medium and R-spondin-1-conditioned me-
diumwas compared to neutral EM containing 10 mMofWnt inhib-
itor IWP-2 (Stemgent) and standard culture medium (neutral EM
plus Wnt3a-conditioned medium and R-spondin-1-conditioned
medium). Organoids were fed with neutral EM for 4 days upon
seeding. Then Wnt agonists or Wnt inhibitor was added for
24 hr. The EdU incorporation assay was used to assess proliferative
activity within the organoids, performed as described earlier. Im-
ages were taken using a confocal microscope (Leica). Quantitative
analysis of EdU-positive cells was performed by Fiji Is Just ImageJ
and ImageJ macros.
For assessment of the role of Wnt and Notch in hepatocellular
differentiation, neutral DM consisting of DM without DAPT was
compared to neutral DMplus 10 mMofWnt inhibitor IWP-2 (Stem-
gent) with or without the presence of 10 nM DAPT (Selleckchem).
IWP-2 was added to the medium from the day organoids were
seeded. DAPT was started after 2 days in culture according to the
normal differentiation protocol. The medium was changed every
other day for a period of 14 days.
COMMD1-DsRed Construct Production and Viral
Transduction
For production of the viral construct, lentivirus was produced us-
ing HEK293T cells. Linear polyethylenimine (PEI) at 1 mg/ml (Pol-Stem Cell Rysciences) was diluted in DMEM and incubated for 5 min at room
temperature (RT). The DNA solution containing HDM-Hgpm2,
RC-CMV-Rev1b, HDM-tat1b, HDM-VSV-G, and pHAGE2-EF1a-
COMMD1-DsRed-PuroR was then mixed with PEI solution (1 mg
DNA:5 mg PEI) and incubated for 10–20 min at RT. The obtained
transfection mix was added to complete mouse embryonic
fibroblast media (cultured in DMEM with 10% FBS), supplied to
the HEK293T cells, and incubated overnight. Media-containing
virus was harvested on days 2–4. Media were ultracentrifuged
at 72,000 g for 1.5–2 hr at 4C. The pellet was resuspended
in 150 ml sterile PBS + 1% BSA, and aliquots were stored at 80C
until use.
For viral transduction, COMMD1-deficient canine hepatic orga-
noids were isolated from frozen liver derived from COMMD1-defi-
cient dogs and cultured as described earlier. Organoids were
removed from Matrigel and underwent mechanical dissociation.
Organoid fragments were incubated with TrypLE select enzyme
(Gibco) for 5 min at 37C to break the fragments into small cell
clusters. The cell clusters were then resuspended in infection
medium containing 8 mg/ml of Polybrene (Sigma-Aldrich) with
lentivirus (1:10,000). Suspensions were transferred to a Costar
ultra-low-attachment 24-well plate (Corning Life Sciences). Spino-
culation was performed for 60min at 32C at 600 g. After spinocu-
lation, the plate with organoids was incubated for 6 hr at 37C
before continuing in Matrigel culture as described earlier. Two
days after transduction, 2 mg/ml of puromycin (Life Technologies)
was added to the medium to select for the transduced cells. A stan-
dard of 0.5 mg/ml of puromycin was used in the culture medium
from 3 days post-transduction. The organoids after viral transduc-
tion are referred as LV-COMMD1-DsRed organoids.Intracellular Copper Measurement
COMMD1-deficient, LV-COMMD1-DsRed, and wild-type organo-
ids were differentiated as described earlier. At day 14 of differenti-
ation, organoids were removed from Matrigel and incubated in
DM containing 500 mM CuCl2 (Sigma-Aldrich) for 3 or 24 hr at
37C. Controls did not contain CuCl2. After washing with PBS,
organoids were incubated with copper fluorescent probe CS1 (Co-
truvo et al., 2015;Miller et al., 2006; Zeng et al., 2006) for 20min at
37C. Organoids were then lysed with radioimmunoprecipitation
assay buffer, and fluorescence was measured at 488 nm. Between
every step, organoids were washed with PBS and centrifuge at
100 g for 5 min. Fluorescence signals were normalized for protein
concentration (Lowry assay, Bio-Rad).
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